Merck & Co., Inc: Pulmonary Arterial Hypertension trials
The registry lists 17 Pulmonary Arterial Hypertension studies with Merck & Co., Inc as lead sponsor. 3 are open to participants now and 11 have results posted.
Phase 1 4Phase 2 7Phase 3 6Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)RecruitingNCT07646860Phase 2
- A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)RecruitingNCT07600723Phase 4
- Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)RecruitingNCT05587712Phase 2
- A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants (MK-7962-020)CompletedNCT05818137Phase 3Results posted
- A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)CompletedNCT04896008Phase 3Results posted
- Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)TerminatedNCT04811092Phase 3Results posted
- A Study of the Efficacy and Safety of Frespaciguat (MK-5475) in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)CompletedNCT04732221Phase 2/3Results posted
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)CompletedNCT04576988Phase 3Results posted
- A Study of Single Doses of Frespaciguat (MK-5475) on Pulmonary Vascular Resistance (MK-5475-002)CompletedNCT03744637Phase 1Results posted
- A Study of Sotatercept for the Treatment of Pulmonary Arterial HypertensionCompletedNCT03738150Phase 2Results posted
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)CompletedNCT03496207Phase 2Results posted
- Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)TerminatedNCT01934647Phase 1Results posted
- Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)CompletedNCT01926509Phase 1Results posted
- A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)CompletedNCT01798849Phase 1Results posted
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)Active, not recruitingNCT07218029Phase 3
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)Active, not recruitingNCT06925750Phase 2
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)CompletedNCT06664801Phase 2